Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease

dc.contributor.authorSmith, Robert X.
dc.contributor.authorStrain, Jeremy F.
dc.contributor.authorTanenbaum, Aaron
dc.contributor.authorFagan, Anne M.
dc.contributor.authorHassenstab, Jason
dc.contributor.authorMcDade, Eric
dc.contributor.authorSchindler, Suzanne E.
dc.contributor.authorGordon, Brian A.
dc.contributor.authorXiong, Chengjie
dc.contributor.authorChhatwal, Jasmeer
dc.contributor.authorJack, Clifford, Jr.
dc.contributor.authorKarch, Celeste
dc.contributor.authorBerman, Sarah
dc.contributor.authorBrosch, Jared R.
dc.contributor.authorLah, James J.
dc.contributor.authorBrickman, Adam M.
dc.contributor.authorCash, David M.
dc.contributor.authorFox, Nick C.
dc.contributor.authorGraff-Radford, Neill R.
dc.contributor.authorLevin, Johannes
dc.contributor.authorNoble, James
dc.contributor.authorHoltzman, David M.
dc.contributor.authorMasters, Colin L.
dc.contributor.authorFarlow, Martin R.
dc.contributor.authorLaske, Christoph
dc.contributor.authorSchofield, Peter R.
dc.contributor.authorMarcus, Daniel S.
dc.contributor.authorMorris, John C.
dc.contributor.authorBenzinger, Tammie L. S.
dc.contributor.authorBateman, Randall J.
dc.contributor.authorAnces, Beau M.
dc.contributor.departmentNeurology, School of Medicine
dc.date.accessioned2024-03-21T12:12:04Z
dc.date.available2024-03-21T12:12:04Z
dc.date.issued2021
dc.description.abstractAim: Identify a global resting-state functional connectivity (gFC) signature in mutation carriers (MC) from the Dominantly Inherited Alzheimer Network (DIAN). Assess the gFC with regard to amyloid (A), tau (T), and neurodegeneration (N) biomarkers, and estimated years to symptom onset (EYO). Introduction: Cross-sectional measures were assessed in MC (n = 171) and mutation noncarrier (NC) (n = 70) participants. A functional connectivity (FC) matrix that encompassed multiple resting-state networks was computed for each participant. Methods: A global FC was compiled as a single index indicating FC strength. The gFC signature was modeled as a nonlinear function of EYO. The gFC was linearly associated with other biomarkers used for assessing the AT(N) framework, including cerebrospinal fluid (CSF), positron emission tomography (PET) molecular biomarkers, and structural magnetic resonance imaging. Results: The gFC was reduced in MC compared with NC participants. When MC participants were differentiated by clinical dementia rating (CDR), the gFC was significantly decreased in MC CDR >0 (demented) compared with either MC CDR 0 (cognitively normal) or NC participants. The gFC varied nonlinearly with EYO and initially decreased at EYO = −24 years, followed by a stable period followed by a further decline near EYO = 0 years. Irrespective of EYO, a lower gFC associated with values of amyloid PET, CSF Aβ1–42, CSF p-tau, CSF t-tau, 18F-fluorodeoxyglucose, and hippocampal volume. Conclusions: The gFC correlated with biomarkers used for defining the AT(N) framework. A biphasic change in the gFC suggested early changes associated with CSF amyloid and later changes associated with hippocampal volume.
dc.eprint.versionFinal published version
dc.identifier.citationSmith RX, Strain JF, Tanenbaum A, et al. Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. Brain Connect. 2021;11(3):239-249. doi:10.1089/brain.2020.0808
dc.identifier.urihttps://hdl.handle.net/1805/39385
dc.language.isoen_US
dc.publisherMary Ann Liebert
dc.relation.isversionof10.1089/brain.2020.0808
dc.relation.journalBrain Connectivity
dc.rightsPublisher Policy
dc.sourcePMC
dc.subjectAmyloid
dc.subjectAutosomal dominant Alzheimer disease
dc.subjectCerebrospinal fluid (CSF)
dc.subjectEstimated years to onset (EYO)
dc.subject18F-fluorodeoxyglucose (FDG)
dc.subjectHippocampus
dc.subjectPositron emission tomography (PET)
dc.subjectResting-state functional connectivity
dc.subjectTau
dc.titleResting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease
dc.typeArticle
ul.alternative.fulltexthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182476/
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Smith2021Resting-PP.pdf
Size:
539.29 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: